Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, reported for the fiscal first quarter ended October 31, 2009, record operating revenues and sharply improved operating results. Related posts Enzo Biochem Schedules [...]

Continue reading " Enzo Biochem Reports Sharply Improved First Quarter Results "

*Multiple Data Presentations at Upcoming AACR-NCI-EORTC, San Antonio Breast Cancer Symposium and ASH Meetings ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, announced financial results for the three-month period ended September 30, 2009 – the first quarter of the Company’s 2010 [...]

Continue reading " ImmunoGen, Inc. Reports First Quarter Fiscal Year 2010 Financial Results "

New England Research Institutes, Inc. (NERI), a global contract research organization (CRO) focused on Phase II-IV clinical trials and ProMedica Clinical Research Center (CRC), Inc., a dedicated Phase I firm, announced their strategic alliance. As a result of this new working relationship, both companies can now provide pharmaceutical, medical device, biomaterial and biotechnology clients with [...]

Continue reading " NERI and ProMedica CRC Form Strategic Alliance to Support Phase I-IV Clinical Research Studies "

Leaders in biotechnology research and patient advocacy joined forces at the 2009 BIO International Convention to discuss the latest breakthroughs in HIV/AIDS treatments. Following a keynote speech by Sir Elton John focused on the needs of the HIV/AIDS community, representatives of biotech companies previewed the next generation of treatments while patient advocates reiterated the need [...]

Continue reading " Biotech Leaders, Patient Advocates Highlight Cutting-Edge HIV/AIDS Therapies, Need for Next Generation Treatments "

Atlanta, Georgia will be the stage for the world’s largest biotechnology conference and tradeshow on May 18-21, 2009. This annual conference is conducted by the Biotechnology Industry Organization (BIO). Related posts Enzo Biochem Reports Sharply Improved First Quarter Results (0) ImmunoGen, Inc. Reports First Quarter Fiscal Year 2010 Financial Results (0) NERI and ProMedica CRC [...]

Continue reading " South Dakota on Display at World’s Largest Biotechnology Conference "

In testimony submitted to the National Institutes of Health (NIH) today, the Biotechnology Industry Organization (BIO) stressed the commitment of its member companies to help ensure that patients and health care providers have access to key clinical trial results information from trials of unapproved products. Related posts Enzo Biochem Reports Sharply Improved First Quarter Results [...]

Continue reading " BIO Members Committed to Ensuring Public Access to Key Clinical Trial Results "

PhiloGene will debut its revolutionary advances in understanding the biology and the treatment of cancer and macular degeneration to a group of eminent venture capitalists and executives from pharmaceutical and biotechnology companies. PhiloGene, through collaboration with Professor David Bates and Dr. Steve Harper at Bristol University in the UK, have found that a novel form [...]

Continue reading " Revolutionary Advances in the Treatment of Cancer and Macular Degeneration "